These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 24325952

  • 1. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C, Egyhazi Brage S.
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [Abstract] [Full Text] [Related]

  • 2. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA.
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM, Long GV.
    Clin Cancer Res; 2014 Apr 15; 20(8):2035-43. PubMed ID: 24583796
    [Abstract] [Full Text] [Related]

  • 5. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M, Voit C.
    Crit Rev Oncol Hematol; 2013 Sep 15; 87(3):239-55. PubMed ID: 23415641
    [Abstract] [Full Text] [Related]

  • 6. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R.
    Pharmacol Res; 2018 Sep 15; 135():239-258. PubMed ID: 30118796
    [Abstract] [Full Text] [Related]

  • 7. Trametinib in metastatic melanoma.
    Chopra N, Nathan PD.
    Expert Rev Anticancer Ther; 2015 Sep 15; 15(7):749-60. PubMed ID: 26107021
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT, McArthur G.
    Cancer; 2010 Nov 01; 116(21):4902-13. PubMed ID: 20629085
    [Abstract] [Full Text] [Related]

  • 10. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, Ascierto PA.
    BioDrugs; 2017 Feb 01; 31(1):51-61. PubMed ID: 28058658
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E, Solit DB.
    Curr Opin Pharmacol; 2008 Aug 01; 8(4):419-26. PubMed ID: 18644254
    [Abstract] [Full Text] [Related]

  • 12. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E, Nikfar S, Niaz K, Faramarzi MA, Abdollahi M.
    Expert Opin Drug Metab Toxicol; 2018 Mar 01; 14(3):317-330. PubMed ID: 29363351
    [Abstract] [Full Text] [Related]

  • 13. BRAF in melanoma: current strategies and future directions.
    Salama AK, Flaherty KT.
    Clin Cancer Res; 2013 Aug 15; 19(16):4326-34. PubMed ID: 23770823
    [Abstract] [Full Text] [Related]

  • 14. Defining and Targeting BRAF Mutations in Solid Tumors.
    Halle BR, Johnson DB.
    Curr Treat Options Oncol; 2021 Feb 27; 22(4):30. PubMed ID: 33641072
    [Abstract] [Full Text] [Related]

  • 15. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.
    Das Thakur M, Stuart DD.
    Clin Cancer Res; 2014 Mar 01; 20(5):1074-80. PubMed ID: 24352648
    [Abstract] [Full Text] [Related]

  • 16. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX, Qi XY.
    IUBMB Life; 2013 Sep 01; 65(9):748-58. PubMed ID: 23893853
    [Abstract] [Full Text] [Related]

  • 17. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P, Picasso V, Spagnolo F.
    Cancer Treat Rev; 2015 Jun 01; 41(6):519-26. PubMed ID: 25944484
    [Abstract] [Full Text] [Related]

  • 18. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
    Heneberg P.
    Klin Onkol; 2012 Jun 01; 25(5):333-9. PubMed ID: 23102194
    [Abstract] [Full Text] [Related]

  • 19. BRAF and MEK inhibition in melanoma.
    Dossett LA, Kudchadkar RR, Zager JS.
    Expert Opin Drug Saf; 2015 Apr 01; 14(4):559-70. PubMed ID: 25648338
    [Abstract] [Full Text] [Related]

  • 20. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK, Kim KB.
    Expert Opin Pharmacother; 2013 Apr 01; 14(5):619-27. PubMed ID: 23432625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.